Active Ingredient History
Mavrilimumab is a human monoclonal antibody that inhibits human granulocyte macrophage colony-stimulating factor receptor (GM-CSF-R). Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Arthritis, Rheumatoid (Phase 2)
COVID-19 (Phase 2/Phase 3)
Giant Cell Arteritis (Phase 2)
Healthy Volunteers (Phase 1)
Lung Diseases (Phase 2)
Pneumonia (Phase 2)
Pneumonia, Viral (Phase 2)
Respiratory Distress Syndrome (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue